scholarly journals Prevalence of Substance Abuse and Related Factors in Type 2 Diabetic Patients Living in a Rural Area in Northern Iran

2020 ◽  
Vol 4 (4) ◽  
pp. 41-49
Author(s):  
Mohammad Shokrzadeh ◽  
Ali Savarolia ◽  
Danial Jafari ◽  
Reza Hoseinpoor ◽  
Hajar Serayeloo ◽  
...  
Keyword(s):  
Substance Abuse ◽  
Rural Area ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Related Factors ◽  
Northern Iran ◽  
Type 2 Diabetic

Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM

Neurology ◽  
2017 ◽  
Vol 88 (10) ◽  
pp. 944-951 ◽  
Author(s):  
Chun-Pai Yang ◽  
Chia-Ing Li ◽  
Chiu-Shong Liu ◽  
Wen-Yuan Lin ◽  
Kai-Lin Hwang ◽  
...  
Keyword(s):  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Diabetic Polyneuropathy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Related Factors ◽  
Fasting Plasma ◽  
Incident Cases ◽  
Type 2 Diabetic

Objective:To examine whether variations in fasting plasma glucose (FPG), as measured by the coefficient of variation (CV), is a predictor of diabetic polyneuropathy (DPN) risk, considering glycated hemoglobin (HbA1c) and other traditional risk factors.Methods:Type 2 diabetic patients enrolled in the National Diabetes Care Management Program were ≥30 years of age and free of DPN (n = 36,152). They were enrolled in 2002–2004 and were monitored until 2011. The related factors were analyzed using Cox proportional hazards regression models.Results:During an average 7.23 years of follow-up, a total of 7,219 incident cases of DPN were identified, with a crude incidence rate of 27.62/1,000 person-years (25.83 for men and 29.31 for women). After multivariate adjustment, both FPG-CV and HbA1c were significant predictors of DPN, with corresponding hazard ratios of 1.14 (95% confidence interval [CI] 1.05–1.23) and 1.15 (95% CI 1.06–1.24) for FPG-CV in the fourth to fifth quintiles and 1.13 (95% CI 1.07–1.20) for HbA1c ≥7%. This finding maintained consistency after excluding potential confounders in the sensitivity analysis, further validating the results.Conclusions:FPG-CV and HbA1c ≥7% were potent predictors of DPN in type 2 diabetic patients. The associations among HbA1c, glycemic variability, and DPN suggest a linked pathophysiologic mechanism, which may play a crucial role in clinical risk assessments.

Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial

2020 ◽  
pp. 1-10
Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Metabolic Control ◽  
Vitamin D3 ◽  
Therapy Group ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

Sign in / Sign up

Export Citation Format

Share Document